Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.66 |
| ▸ | PPARA | Q07869 | 16/20 | 0.66 |
| ▸ | PPARD | Q03181 | 8/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694804 | 0.94 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL4693200 | 0.92 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL4689724 | 0.91 | PPARG (0.81) | PPARGPPARAPPARD | |
| SCHEMBL14144777 | 0.90 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4692405 | 0.88 | PPARG (0.80) | PPARGPPARAPPARD | |
| SCHEMBL4693382 | 0.87 | PPARG (0.53) | PPARGPPARAPPARD | |
| SCHEMBL14145129 | 0.84 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL4693407 | 0.82 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL2807117 | 0.82 | PPARG (0.77) | PPARGPPARAPPARD | |
| SCHEMBL4692677 | 0.80 | PPARG (0.67) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020078788-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | WO | claimed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | claimed |
| EP-2558126-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-02-20 | — | — | EP | claimed |
| WO-2011128407-A9 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | claimed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | claimed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | claimed |
| JP-2007511485-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | claimed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2019197269-A1 | COMBINATIONS OF COPANLISIB WITH TRIAZOLONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| EP-3268005-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016142313-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | WO | disclosed |
| EP-2694069-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | disclosed |
| EP-2558126-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-02-20 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.